IR Biosciences Holdings Inc.
IRBS · OTC
12/31/2010 | 9/30/2010 | 6/30/2010 | 3/31/2010 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | 0.00 |
| FCF Yield | -891,212.64% | 0.00% | 0.00% | -2,017,772.82% |
| EV / EBITDA | 25.90 | -1.24 | 4.05 | -2.24 |
| Quality | ||||
| ROIC | 14.34% | 14.68% | 59.06% | 66.56% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.44 | – | – | 0.08 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 100.00% | 44.66% |
| Safety | ||||
| Net Debt / EBITDA | 25.90 | -1.24 | 4.05 | -2.24 |
| Interest Coverage | -0.83 | -1.40 | -2.48 | -1.80 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |